VTE Prophylaxis for Surgical Patients
All surgical patients without contraindications should receive risk-stratified VTE prophylaxis using pharmacological agents (LMWH or UFH) based on their Caprini score, with LMWH preferred as first-line therapy for at least 7-10 days, and extended to 4 weeks for high-risk cancer surgery patients.
Risk Assessment Framework
Use the Caprini Risk Assessment Model to stratify all surgical patients 1, 2:
- Very Low Risk (Caprini 0): Early ambulation only, no additional prophylaxis 2
- Low Risk (Caprini 1-2): Mechanical prophylaxis (intermittent pneumatic compression preferred) OR pharmacological prophylaxis 2
- Moderate Risk (Caprini 3-4): LMWH, UFH, or mechanical prophylaxis if bleeding risk is high 2
- High Risk (Caprini ≥5): Pharmacological prophylaxis (LMWH or UFH) PLUS mechanical prophylaxis 2
Pharmacological Prophylaxis: Agent Selection
LMWH is the preferred first-line agent over UFH for most surgical patients 1, 3, 4. The advantages include once-daily dosing, superior pharmacokinetics, and lower risk of heparin-induced thrombocytopenia 4.
Standard Dosing Regimens 5, 6, 5:
LMWH options:
- Enoxaparin: 40 mg subcutaneously once daily (or 20 mg preoperatively, then 40 mg daily)
- Dalteparin: 5,000 units subcutaneously once daily (or 2,500 units preoperatively, then 5,000 units daily)
UFH alternative:
- 5,000 units subcutaneously every 8 hours (three times daily dosing is more effective than twice daily) 5
Fondaparinux (2.5 mg subcutaneously once daily starting 6-8 hours postoperatively) is an acceptable alternative when LMWH is unavailable 1, 3, 5.
Timing of Initiation
Start prophylaxis 2-4 hours preoperatively or 10-12 hours preoperatively depending on the regimen 5, 6, 5. Postoperative initiation (6-8 hours after surgery) is acceptable for fondaparinux 5.
Duration of Prophylaxis
Standard Duration
Continue prophylaxis for at least 7-10 days for all surgical patients, or until the patient is fully ambulatory and discharged 5, 6, 7.
Extended Duration (4 Weeks)
Extended prophylaxis with LMWH for 4 weeks is strongly recommended for patients undergoing major abdominal or pelvic cancer surgery who are at high risk for VTE 1, 3, 2. This applies to:
- Major open or laparoscopic abdominal/pelvic cancer surgery
- Patients with additional high-risk features: restricted mobility, obesity, history of VTE, or other risk factors 1, 6
- Colorectal cancer resection patients at high VTE risk 1
The evidence supporting extended prophylaxis in cancer surgery is robust (Grade 1A/1B), showing 60% reduction in VTE risk without increased bleeding 4, 2.
Special Populations
Cancer Surgery Patients
All patients with malignancy undergoing major surgery should receive pharmacological prophylaxis unless contraindicated by active bleeding or high bleeding risk 5, 6, 7. For cancer patients:
- Use high-dose LMWH (e.g., enoxaparin 40 mg or dalteparin 5,000 units once daily) rather than lower doses 4
- Extend prophylaxis to 4 weeks for major abdominopelvic cancer surgery 1, 3
- Consider LMWH over fondaparinux as the preferred agent 1
High Bleeding Risk Patients
For patients at high risk for major bleeding complications or where bleeding consequences would be severe:
- Use mechanical prophylaxis (preferably intermittent pneumatic compression) as monotherapy until bleeding risk diminishes 2
- Then transition to pharmacological prophylaxis when safe 2
- Do not use mechanical methods as monotherapy unless pharmacological prophylaxis is contraindicated 4, 7
Mechanical Prophylaxis
Mechanical methods (graduated compression stockings or intermittent pneumatic compression) should be:
- Added to pharmacological prophylaxis in very high-risk patients (Caprini ≥5) 2
- Used as temporary monotherapy only when anticoagulation is contraindicated 4, 7
- Intermittent pneumatic compression is preferred over compression stockings 2
What NOT to Do
- Do not use prophylactic IVC filters for routine VTE prevention 3, 2
- Do not perform surveillance compression ultrasonography in asymptomatic patients 2
- Do not use mechanical prophylaxis alone in moderate to high-risk patients who can receive anticoagulation 4
Common Pitfalls
Underdosing in cancer patients: Use high prophylactic doses (enoxaparin 40 mg, not 20 mg; dalteparin 5,000 units, not 2,500 units) 4
Stopping prophylaxis too early in cancer surgery: Extend to 4 weeks for major abdominopelvic cancer operations 1, 3
Forgetting preoperative dosing: Initiate prophylaxis preoperatively (2-12 hours before surgery) for optimal efficacy 3, 5
Using UFH twice daily: Three times daily dosing (every 8 hours) is more effective than twice daily 5
Relying solely on mechanical prophylaxis: This should only be used as monotherapy when pharmacological prophylaxis is contraindicated by bleeding risk 4, 7